Therapeutic effect of all-trans retinoic acid on rats with anti-GBM antibody glomerulonephritis.
regulate inflammatory and proliferative responses makes them attractive potential candidates for therapeutic use in renal disease.
In the present study, we tested the therapeutic efficacy of ATRA on anti-GBM antibody-induced renal injury. We started the ATRA therapy at 14 days after disease induction, when the disease is fully developed.
We found that urinary protein excretion was reduced in ATRA-treated group along with a significant attenuation of glomerular injury. A wide variety of glomerular gene expression was suppressed in ATRA-treated group, which may partly contribute to the therapeutic efficacy of ATRA on renal disease.
METHODS

Experimental protocol
Male Wistar-Kyoto rats, aged 12 weeks, were used in the present study. Glomerulonephritis was induced in 15 rats on day 0 by a single intravenous injection of 25 L/ 100 g body weight of anti-rat GBM antiserum as previously reported [7] . Five rats were sacrificed on day 14. We divided the remaining 10 rats into two groups: the vehicle group, the anti-GBM glomerulonephritis without treatment (N ϭ 5), and the ATRA-treated group (N ϭ 5), the anti-GBM glomerulonephritis group treated by ATRA. ATRA was mixed with sesame oil (9 mg/mL) and was orally administrated at a dose of 30 mg/kg body weight using gavage tube once daily from day 14 to day 27. Blood pressure and body weight was determined on days 1, 14, 21, and 27. Blood pressure was measured by blood pressure monitor for rats and mice model MK-1100 (Muromachi Kikai Co., Ltd., Tokyo, Japan).
Proteinuria and creatinine determination
For determination of urinary protein excretion, rats were placed in metabolic cages and urine was collected for 24 hours on days 1, 14, 21, and 27. Blood samples were taken from tail vein on the same time points. Urinary protein concentration was determined by pyrogallol red-molybdate complex method using a Micro TP-test WAKO (Wako Pure Chemical Industries, Ltd., Osaka, Japan) [8] . Serum and urinary creatinine concentration was determined by Jaffe method using a Creatinine-test WAKO (Wako Pure Chemical Industries, Ltd.).
RNA isolation from glomeruli
Both vehicle-treated rats and ATRA-treated rats were sacrificed on day 28. Both kidneys were removed and partially preserved for histologic analysis. Glomeruli were isolated by differential sieving as described previously [9] . Glomerular total RNA was extracted from isolated glomeruli by the acid guanidinium thiocyanatephenol-chloroform method [10] . Abbreviations are: GADPH, glyceraldehyde-3-phosphate dehydrogenase; TNF-␣, tumor necrosis factor-␣; IL-1ß, interleukin-1ß; TGF-ß1, transforming growth factor-1ß; MCP-1, monocyte chemoattractant protein-1;
␣-SMA, ␣-smooth muscle actin; ICAM-1, intercellular adhesion molecule-1; PDGF, platelet-derived growth factor; C-EBS␦, CCAAT enhancer-binding protein ␦.
Semiquantitative reverse transcription-polymerase chain reaction
Reverse transcription (RT) was performed as follows: 4 L first-strand RT buffer was added to 0.4 g of total RNA from isolated glomeruli [ The primers that we used are listed in Table 1 . The primers for glyceraldehyde-3-phosphate dehydrogenase (GAPDH), interleukin-1␤ (IL-1␤), tumor necrosis factor-␣ (TNF-␣), TGF-␤1, and monocyte chemoattractant protein-1 (MCP-1) were used as described previously [11] . The primers for type I collagen (collagen I) were used as previously reported [12] . The primers for intercellular adhesion molecule-1 (ICAM-1) were used as previously reported [13] . The primers for rat c-fos, c-jun and ␣-smooth muscle actin (␣-SMA) were constructed based on rat c-fos, c-jun and ␣-SMA nucleotide sequences. The primers for platelet-derived growth factor (PDGF) and CCAAT enhancer-binding protein ␦ (C/EBP␦) were designed based on mouse PDGF and C/EBP␦ nucleotide sequences.
All PCR was performed using a thermal cycler, PCR System 9700 (Perkin Elmer, Wellesley, MA, USA), using the following parameters. After initial denaturation for 5 minutes at 95ЊC, 25 to 32 cycles of sequential steps denaturation was performed at 95ЊC for 1 minute, annealing at 55 to 64ЊC for 1 minute, extension at 72ЊC for 2 minutes, followed by a final incubation at 72ЊC for 7 minutes. The primers and PCR conditions for each primer set are summarized in Table 1 .
The PCR products were separated by electrophoresis on 2.0% agarose gels and visualized by ethidium bromide staining. Each experiment included the amplification of GAPDH, and the intensities of cDNA bands were quantified with the computing densitometry Image Quant (Molecular Dynamics, Sunnyvale, CA, USA), and were normalized to those of the GAPDH band as reported previously [12] .
Histologic examination
The kidneys were perfused with cold autoclaved phosphate-buffered saline (PBS) and were removed. Tissues for microscopic examination were fixed with 4% paraformaldehyde overnight and then dehydrated by graded ethanol, then paraffin embedded. Thin section was examined with periodic acid-Schiff (PAS) staining as described previously [14] . Fifty glomeruli per section were randomly selected and were assessed. Glomerular appearance was graded as normal, mild to moderate, or severe injury (Ͼ50% of glomerulus affected by necrosis/ crescent formation), and results were expressed as percentage of glomeruli examined. At the same time, glomerular area and necrosis/crescent formation area were quantitatively measured under high-power magnification (ϫ400) by using computer-aided manipulator program (Macscope; Mitani Corporation, Fukui, Japan), and the percentage of the glomerular necrosis/crescent formation area was calculated.
Immunohistochemistry
PBS-perfused slices (4 m) of renal tissue obtained from comparable renal areas in all rats were fixed in methacarn solution (methanol 60%, chloroform 30%, and acetic acid 10%) and processed using the direct or indirect immunoperoxidase technique. The endogenous peroxidase activity in tissue sections was blocked by incubating in PBS with 3% hydrogen peroxide for 30 minutes. Tissue sections were preincubated with goat or horse serums diluted 1:20 with PBS for 30 minutes to block the nonspecific staining and were then incubated with the primary antibodies for 60 minutes at room temperature. Glomerular cell proliferation was assessed by staining with 19A2 (Coulter Corp., Hialeah, FL, USA), a mouse monoclonal immunoglobulin M (IgM) antibody to the proliferative cell nuclear antigen (PCNA). To assess the invasion of macrophages, mouse IgG antirat monocyte and macrophage (ED-1) antibody was used (Serotec, Inc., Raleigh, NC, USA). To stain ␣-SMA, mouse IgG anti-SMA monoclonal antibodies were used (Immunotech S.A., Cedex, Marseilles, France). To stain C/EBP␦, rabbit IgG anti-C/EBP␦ monoclonal antibodies (M-17) was used (Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA). Sections were then processed using an avidin-biotinylated peroxidase complex method (Vectastain ABC kit; Vector Laboratories, Inc., Burlingame, CA, USA) with diaminobenzidine as the chromogen. The sections were counterstained with methyl green. Sections labeled with PCNA and ED-1 monoclonal antibodies were scored by the number of PCNA-positive cells and ED-1-positive cells within the glomerulus. Count- Fig. 1 . Effect of all-trans retinoic acid (ATRA) administration on anti-glomerular basement membrane (anti-GBM) glomerulonephritis. Periodic acid-Schiff (PAS) staining of kidney on day 14 in anti-GBM glomerulonephritis rats (A), on day 28 in vehicle-treated rats (B), and ATRA-treated rats (C). The severity of glomerular injury was graded as normal, mild to moderate, or severe (Ͼ50% of glomerulus affected by necrosis/crescent formation) (D). Vehicle-treated rats showed 89% injured glomeruli, with severe segmental necrosis/crescent formation affecting 34% of glomeruli. ATRA-treated rats showed 67% injured glomeruli, with severe change in 14%. Glomerular necrosis/crescent formation area was quantitatively analyzed by computer-aided manipulator program (E). The area was 24.9 Ϯ 3.9% on day 14. The area on day 28 in vehicle rats was 33.1 Ϯ 5.7% and 17.9 Ϯ 4.4% in ATRA-treated rats. ᭣ ing of the marker positive cells was performed under high-power (ϫ 400) microscopy. The number of PCNApositive cells and ED-1-positive cells per glomerulus was determined by the observation of randomly selected 50 glomeruli for each animal. All scoring was performed on blinded slides by one of the authors. Glomerular ␣-SMApositive and C/EBP␦ area was quantitatively analyzed by using computer-aided manipulator program, Macscope (Mitani Corporation), as described previously [15, 16] .
Statistical analysis
The results were given as means Ϯ standard deviation. The differences between vehicle-treated and ATRAtreated groups were tested using the Student t test. Statistically significant differences between groups were defined as P values less than 0.05.
RESULTS
ATRA reduced renal injury
We examined whether ATRA administration could ameliorate the renal injury of anti-GBM glomerulonephritis rats. On day 14, light microscopy of kidney tissue of anti-GBM glomerulonephritis rats showed diffuse necrotizing glomerulonephritis affecting 81% of glomeruli, with severe segmental necrosis/crescent formation (Ͼ50% of the glomerulus) affecting 14% of glomeruli. On day 28, vehicle-treated rats showed diffuse necrotizing glomerulonephritis affecting 89% of glomeruli, with severe necrosis/crescent formation affecting 34% of glomeruli. ATRA-treated rats showed diffuse necrotizing glomerulonephritis affecting 67% of glomeruli, with severe change in 14% (Fig. 1D) . Computer-aided quantitative analysis revealed that glomerular necrosis/crescent formation area was also reduced from 33.1 Ϯ 5.7% to 17.9 Ϯ 4.4% (P Ͻ 0.01) (Fig. 1E) . We examined whether ATRA could decrease the glomerular cell proliferation assessed by the PCNA expression. The number of PCNApositive cells per glomerulus in ATRA-treated rats was (Fig. 3) . To examine the degree of phenotypic change of glomerular cells to myofibroblasts, we measured the ␣-SMA-positive area of glomeruli. The ␣-SMA-positive area was significantly reduced from 8.3 Ϯ 1.3% to 3.7 Ϯ 0.3% by ATRA administration (Fig. 4) . To examine protein levels of C/EBP␦ in glomerulus, we performed the immunostaining of C/EBP␦ and measured the C/EBP␦-positive area of glomeruli. The C/EBP␦-positive area was significantly reduced from 21.9 Ϯ 4.2% to 14.2 Ϯ 3.5% by ATRA administration (Fig. 5 ) on day 28. Of note, there was no immunostaining of C/EBP␦ in normal rat glomeruli, suggesting its involvement in the pathologic process in glomeruli (Fig. 5) .
Effects of ATRA on glomerular gene expression
Histologic examination demonstrated that ATRA administration ameliorated glomerular injury in anti-GBM glomerulonephritis. To explore the underlying mechanisms of this therapeutic efficacy, we examined the effects of ATRA administration on glomerular gene expression of wide variety of genes, including inflammation-related, cell proliferation-related, and fibrosis-related genes by semiquantitative PCR. TNF-␣ and IL-1␤ mRNAs were significantly reduced in ATRA-treated rats (Fig. 6) . TGF-␤1, type I collagen, and ␣-SMA mRNA was reduced in ATRA-treated rats compared with vehicle-treated rats (Fig. 7) . PDGF, MCP-1, and ICAM-1 mRNA was also significantly suppressed in ATRA-treated rats (Fig. 8) . Additionally, c-fos and c-jun mRNAs, which are components of activated protein 1 (AP-1), were significantly reduced in ATRA-treated rats (Fig. 9) . C/EBP␦ mRNA was significantly reduced in ATRA-treated rats (Fig. 10) , 
Body weight
There was no significant difference in body weight between the vehicle-treated and ATRA-treated rats (day 1, 300 Ϯ 9.6 g vs. 301 Ϯ 9.0 g; day 14, 339 Ϯ 11.8 g vs. 334 Ϯ 7.4 g; day 27, 350 Ϯ 14.6 g vs. 342 Ϯ 11.0 g).
Urinary protein excretion
The rate of urinary protein excretion was markedly increased after injection of anti-rat GBM antibody both in vehicle-and ATRA treated glomerulonephritis rats before the commencement of ATRA treatment. In ATRA-treated group, the rate of urinary protein excretion was significantly reduced. On day 21, 7 days after the commencement of ATRA therapy, the rate of proteinuria was reduced to 46% of that of vehicle-treated rats in ATRA-treated rats and the suppression was continued until day 27 (Fig. 11) . Creatinine clearance or serum creatinine levels were not different between vehicle-and ATRA-treated groups (data not shown).
Blood pressure
There was no significant difference in blood pressure between the vehicle-treated and ATRA-treated groups just before the commencement of ATRA administration. On day 21, 7 days after ATRA treatment was started, blood pressure was not different, but on day 27, 14 days after the beginning of ATRA administration, blood pressure was significantly lower in ATRA-treated rats compared to vehicle-treated rats (Fig. 12) .
DISCUSSION
In the present study, intravenous injection of antirat GBM antibody induced necrotizing glomerulonephritis affecting 81% of glomeruli and severe segmental necrosis/crescent formation affecting 14% of glomeruli on day 14, and severe segmental necrosis/crescent formation increased to 34% of glomeruli on day 28 in vehicle-treated ᭣ Fig. 4 . Effect of all-trans retinoic acid (ATRA) administration on glomerular ␣-smooth muscle action (␣-SMA) expression. Representative immunohistochemical photomicrographs of glomeruli stained for ␣-SMA on day 28 in vehicle-treated rats (A), and ATRA-treated rats (B). Five animals were analyzed for each group and 50 randomly selected high-power fields were quantitated with a computer-aided image manipulator and averaged to obtain the value for each animal(C). ␣-SMA-positive area in anti-GBM glomerulonephritis on day 14 was 4.7 Ϯ 1.1%. The area in vehicle-treated rats was 8.3 Ϯ 1.3% and 3.7 Ϯ 0.3% in ATRA-treated rats (P Ͻ 0.01).
rats. In this anti-GBM glomerulonephritis rat model, acute glomerular injuries show a peak around day 15 and then sclerotic/fibrotic glomerular lesions develop thereafter [17] . The percentages of affected glomeruli in the present study are similar to those in the previous report [18] . Anti-GBM glomerulonephritis rats showed about 100 mg/day of proteinuria on day 14, which is comparable to the level of proteinuria induced by the same anti-GBM antibody [19] . In our experiment, ATRA administration significantly reduced renal injury and urinary protein excretion. In immunohistochemical study, ATRA reduced the number of PCNA or ED-1-positive cells in glomeruli. We also found that ATRA suppressed mRNA expression of proliferation and inflammatoryrelated genes, which may partly contribute to ATRA's antiproliferative and anti-inflammatory effects on glomerular injury.
The substantial local macrophage proliferation within Bowman's space in crescentic lesion has already been documented in anti-GBM glomerulonephritis rats by double staining of ED-1 and PCNA [20] . We stained PCNA and ED-1 on consecutive sections and found considerable overlapping of ED-1-positive cells in PCNA-positive cells, although we did not perform double staining. We speculate that some population of PCNA-positive cells in glomeruli was ED-1-positive macrophages.
It is now well established that glomerular macrophage infiltration is closely related to the progression of renal injury [21] . We found that ATRA administration significantly suppressed the glomerular macrophage infiltration. Glomerular expression of ICAM-1 and MCP-1 was also significantly suppressed in ATRA-treated rats. Up-regulation of glomerular ICAM-1 and MCP-1 expression was previously demonstrated in anti-GBM glomerulonephritis rats [7, 22] . Administration of anti-ICAM-1 antibody [22] or anti-MCP-1 antibody [7] significantly suppressed macrophage infiltration and urinary protein excretion in this model. These results suggest that enhanced expression of ICAM-1 and MCP-1 play a crucial role in renal injury Representative immunohistochemical photomicrographs of glomeruli stained for C/EBP␦ on day 28 in normal rats (A), vehicle-treated rats (B), and ATRAtreated rats (C). Five animals were analyzed for each group and 50 randomly selected high-power fields were quantitated with a computer-aided image manipulator and averaged to obtain the value for each animal(D). C/EBP␦-positive area in anti-glomerular basement membrane (anti-GBM) glomerulonephritis on day 14 was 30.4 Ϯ 3.9%. The area in vehicle-treated rats was 21.9 Ϯ 4.2% and 14.2 Ϯ 3.5% in ATRA-treated rats (P Ͻ 0.01). Fig. 6 . Effects of all-trans retinoic acid (ATRA) administration on proinflammatory glomerular gene expression in anti-glomerular basement membrane (anti-GBM) glomerulonephritis rats. (A ) Ethidium bromide-stained gels. Vehicle-treated rats and ATRA-treated rats. The level of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was not of anti-GBM glomerulonephritis. The reduction of renal macrophage infiltration and proteinuria in our experiment may partly be due to the attenuation of ICAM-1 or MCP-1 mRNA expression. Proinflammatory cytokines such as TNF-␣, IL-1␤, and nitric oxide are known to activate macrophages. ATRA decreased the level of nitric oxide and TNF-␣ in macrophage cell line [23] . In our study, glomerular TNF-␣ and IL-1␤ mRNA expression was reduced in ATRA-treated rats. This result suggests that ATRA reduces such proinflammatory cytokines and attenuates macrophage activity. The attenuation of macrophage infiltration and activation may be one of the unsignificantly different. Tumor necrosis factor-␣ (TNF-␣) and interleukin-1␤ (IL-1␤) mRNA expression was significantly reduced by ATRA administration. The intensities of cDNA bands were quantified with the computing densitometry and normalized by GAPDH. (B) TNF-␣ mRNA was decreased to 55% and (C) IL-1␤ mRNA was decreased to 44% in ATRA-treated rats compared with vehicle-treated rats. derlying mechanisms of the therapeutic effect of ATRA on anti-GBM antibody glomerulonephritis.
ATRA was shown to down-regulate H 2 O 2 -induced [24] and fetal bovine serum (FBS)-stimulated [25] expression of c-fos and c-jun in cultured mesangial cells. In our study, glomerular c-fos and c-jun mRNAs were reduced in ATRA-treated rats in vivo. Previous study demonstrated that down-regulation of c-fos and c-jun mRNA levels suggests a mechanism for anti-AP-1 activity by ATRA [25] . Thus, the blunted gene expression of c-fos and c-jun mRNA in ATRA-treated rats is supposed to result in the down-regulation of AP-1 activity in the glomeruli. MCP-1 expression is reported to be partly regulated by AP-1 activation [26, 27] . MCP-1 production stimulated by IL-1␤ was suppressed via inhibition of nuclear factor-kappa B (NF-B) and AP-1 activation [28] . On the other hand, overexpression of AP-1 protein induced ICAM-1 gene expression [29] . Taken together, down-regulation of ICAM-1 and MCP-1 in ATRA-treated rats may at least partly be explained by the suppressive effects of ATRA on c-fos and c-jun mRNAs. There have been some reports demonstrating that AP-1 regulates TGF-␤ gene expression in variety of cells, including mesangial cells and tubular cells [30] [31] [32] [33] . TGF-␤1 mRNA expression was decreased in ATRA-treated rats in our study, which might be related to the suppression of AP-1 component genes. Morath et al [34] also suggested that the beneficial effects of ATRA on anti-Thy1.1 nephritis may be due to a suppression of renal TGF-␤1. TGF-␤ is supposed to play a central role in the progression of tissue fibrosis via stimulation of extracellular matrix components (ECM) synthesis and cellular phenotypic change to myofibroblasts. ␣-SMA is one of the typical molecular markers of myofibroblasts and is known to be induced by TGF-␤ [35] . The reduction of TGF-␤1 mRNA expression may result in the reduction of glomerular myofibroblast expansion revealed by ␣-SMA expression and reduction of type I collagen mRNA expression.
Myofibroblasts are recognized as the key to understand the reconstruction and excessive matrix formation in injured tissue. We have been investigating the phenotypic change from renal cells to myofibroblasts in the process of progressive renal diseases in animal models and human glomerulonephritis [15, 35, 36] . ␣-SMA is a typical molecular marker of myofibroblasts, and we hypothesized that the molecular mechanisms underlying the induction of ␣-SMA in myofibroblasts are closely Fig. 11 . Effect of all-trans retinoic acid (ATRA) administration on urinary protein excretion in anti-glomerular basement membrane (anti-GBM) glomerulonephritis rats. Urinary protein excretion was decreased to 46% of untreated levels 7 days after ATRA administration. *P Ͻ 0.05 vehicle vs. ATRA treated rats. Fig. 12 . Effect of all-trans retinoic acid (ATRA) administration on blood pressure in anti-glomerular basement membrane (anti-GBM) glomerulonephritis rats. There was no difference between two groups 7 days after ATRA administration, but blood pressure was significantly lower in ATRA-treated group 14 days after the beginning of ATRA administration. *P Ͻ 0.05 vehicle vs. ATRA-treated rats.
related to the molecular pathophysiology of progressive renal disease leading to renal fibrosis. We speculated any factor that promotes ␣-SMA expression might play an important role for transdifferentiation to myofibroblast and progression of tissue injury. Then, we identified C/EBP␦ as a major transcription factor that induces phenotypic change in renal disease. We also found that C/EBP␦-deficient mice show a significant reduction in ␣-SMA expression along with substantial amelioration in renal damage in Habu venom glomerulonephritis or unilateral ureteral obstruction. In the present study, we demonstrated a significant reduction of both C/EBP␦ and ␣-SMA mRNA or protein expression in glomeruli from ATRA-treated anti-GBM glomerulonephritis rats. This observation and our results of other study using C/ EBP␦-deficient mice further support the role of C/EBP␦ in myofibroblast formation [(manuscript in preparation) abstract; Takeji M, et al, J Am Soc Nephrol 13:295A, 2002]. We speculate that the suppression of C/EBP␦ mRNA is at least part of the molecular mechanism of therapeutic effect of ATRA in anti-GBM glomerulonephritis.
It was already demonstrated that ATRA lowered the high blood pressure in anti-Thy1.1 glomerulonephritis rats [6] . In our experiment, blood pressure of ATRAtreated rats was significantly lower compared with vehicle-treated rats 14 days after ATRA administration, although no significant difference was observed after 7 days of treatment. Interestingly, it was recently shown that ATRA might have an inhibitory effect on reninangiotensin system (RAS) in the kidney [37] . Thus, the lower blood pressure at 14 days after ATRA administration may be related to the suppression of RAS component genes, and alternatively, be secondary to the amelioration of renal injury by ATRA treatment.
CONCLUSION
We have demonstrated therapeutic effects of ATRA on anti-GBM antibody glomerulonephritis rats revealed by histologic changes, urinary protein excretion, and blood pressure. A wide variety of disease-related gene expression in glomeruli was blunted in ATRA-treated rats, which may explain the molecular mechanisms of therapeutic effects of ATRA in glomerulonephritis rats. Clinical feasibility of ATRA treatment in progressive renal diseases is expected to be established with further investigation.
